ReviewFrontiers in endocrinology2026
Obesity and cryptorchidism across development: an integrated endocrine and metabolic life course framework.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Childhood obesity is a major endocrine and metabolic disorder that extends beyond cardiometabolic risk and may affect male reproductive development. Cryptorchidism (undescended testis, UDT) is a common congenital anomaly associated with hypogonadism, subfertility, and testicular cancer. However, endocrine and metabolic links between obesity and impaired testicular descent remain incompletely integrated. Objective: This mini review synthesizes current evidence into an integrated life-course framework explaining how obesogenic exposures, including maternal metabolic disease, postnatal adiposity, and endocrine disrupting chemicals (EDCs), may interfere with testicular descent and gonadal maturation. Methods: We integrate human and experimental evidence across prenatal life, minipuberty, childhood, and puberty, focusing on Leydig cell hormones (INSL3 and testosterone), hypothalamic-pituitary-gonadal (HPG) axis regulation, sex hormone binding globulin (SHBG), aromatase activity, leptin and insulin signaling, and EDC exposure. Results: Maternal obesity and gestational metabolic disorders may be associated with an inflammatory and hormonal milieu that could plausibly impair Leydig cell function and influence testicular development. Postnatal and adolescent obesity may shift sex steroid balance through increased aromatization, reduced SHBG, and altered central gonadotropin signaling, potentially influencing gonadal maturation and testicular position maintenance. EDCs with anti-androgenic and obesogenic properties may amplify these disturbances across development. Conclusions: Integrating endocrine and metabolic mechanisms places cryptorchidism within a broader developmental and metabolic context rather than as an isolated anatomic anomaly.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.